Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q2 2022 Earnings Presentation
12 slides from Adc Therapeutics Sa's earnings presentation, Aug 9, 2022
Slide 1: 2Q 2022 Earnings Call
2Q 2022 Earnings Call August 9, 2022
Slide 2: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Ameet Mallik Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 02 Chief Commercial Officer Joseph Camardo Clinical Highlights 03 Chief Medical Officer Jenn Creel 04 Chief Financial Officer Financial Update 3
Slide 4: Maximizing Value in the Near, Mid- and Long-Term
Maximizing Value in the Near, Mid- and Long-Term Broadening our ADC Platform and Short-Mid Term Mid-long Term Developing PBD-Based Leadership Establishing Global Solid Tumor Portfolio Hematology Business § Accelerate current research programs § Complete Phase 1 studies for Cami + to the clinic § Max
Slide 5: ZYNLONTA: 2Q 2022 Net Sales of $17.3 million
ZYNLONTA: 2Q 2022 Net Sales of $17.3 million Significant Opportunity in the 3L+ DLBCL Market Academic Community § Initial focus of the launch § Broader opportunity where the majority of the DLBCL patient population is treated vs. academic § Engaged and educated specialists/thought leaders centers wh
Slide 6: ZYNLONTA: Targeted Plan to Capture Significant Opportunity in 3L+ DLBCL Market
ZYNLONTA: Targeted Plan to Capture Significant Opportunity in 3L+ DLBCL Market Physicians Optimizing execution of all customer-facing teams with increasing face-to-face opportunities in order to capture broader and deeper market share in both academic and community centers Community Partnering with
Slide 7: Focused ZYNLONTA Strategy To Maximize Potential
Focused ZYNLONTA Strategy To Maximize Potential LOTIS-7 Novel combinations § Phase 1 trial of ZYNLONTA in multiple NHL novel combinations § Initiated in June 2022, enrollment ongoing LOTIS-9 1L DLBCL unfit/frail § Exploratory Phase 2 trial in combination with rituximab § Initiated in July 2022, enro
Slide 8: Progressing Cami in HL toward BLA
Progressing Cami in HL toward BLA Phase 2 top-line data at EHA congress demonstrated encouraging antitumor activity as a single agent: § ORR of 70.1% § CRR 33.3% § Median duration of response of 13.7 months for all responders § No new safety signals § 117 patients with a median 6 lines of prior ther
Slide 9: Solid Tumor Franchise: Leveraging Validated ADC Platform
Solid Tumor Franchise: Leveraging Validated ADC Platform Cami § Targeting advanced solid tumors with evidence of CD25(+) Treg content Targeting CD25 § Phase 1b trial of Cami + pembrolizumab: Safety and efficacy data anticipated in 2023 § Novel, first-in-class asset targeting solid tumors including p
Slide 10: 2Q and 1H 2022 Financial Update (in $ millions)
2Q and 1H 2022 Financial Update (in $ millions) Cash runway into early 2025 based on current business plan and expected milestones from Sobi and Healthcare Royalty Partners Current cash balance of $377M does not include upfront payment of $55M received from Sobi in July 2022 Balance Sheet June 30, 2
Slide 11: Anticipated Development Milestones
Anticipated Development Milestones Hematology Programs ZYNLONTA: q 1H 2022: Initiate randomized portion of the LOTIS-5 confirmatory trial in combination with rituximab q 1H 2022: Initiate ZYNLONTA trial in multiple combinations in NHL q 2H 2022: Initiate LOTIS-9 trial of ZYNLONTA + rituximab in 1L u
Slide 12: 2Q 2022 Earnings Call
2Q 2022 Earnings Call THERAPEUTICS Innovating Science. Inspiring Hope.